Meta-Analysis
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Oct 15, 2023; 14(10): 1573-1584
Published online Oct 15, 2023. doi: 10.4239/wjd.v14.i10.1573
Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: A meta-analysis
Chu Lin, Zong-Lin Li, Xiao-Ling Cai, Sui-Yuan Hu, Fang Lv, Wen-Jia Yang, Li-Nong Ji
Chu Lin, Zong-Lin Li, Xiao-Ling Cai, Sui-Yuan Hu, Fang Lv, Wen-Jia Yang, Li-Nong Ji, Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing 100044, China
Author contributions: Ji LN and Cai XL were responsible for the study concept and designed the systematic review protocol; Lin C and Li ZL performed the study selection and data extraction; Lin C and Li ZL performed the statistical analyses; Lin C, Li ZL and Cai XL prepared the outlines and wrote the manuscript; All authors contributed to the critical revision of manuscript drafts.
Supported by Beijing Natural Science Foundation, No. 7202216; National Natural Science Foundation of China, No. 81970698 and No. 81970708.
Conflict-of-interest statement: LJ has received fees for lecture presentations and for consulting from AstraZeneca, Merck, Metabasis, MSD, Novartis, Eli Lilly, Roche, Sanofi-Aventis and Takeda. All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare. No other support from any organization for the submitted work other than that described above.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Nong Ji, MD, Professor, Department of Endocrinology and Metabolism, Peking University People’s Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, China. jiln@bjmu.edu.cn
Received: June 8, 2023
Peer-review started: June 8, 2023
First decision: July 18, 2023
Revised: July 22, 2023
Accepted: August 17, 2023
Article in press: August 17, 2023
Published online: October 15, 2023
Processing time: 123 Days and 5.3 Hours
Core Tip

Core Tip: This is the first indirect meta-analysis comparing efficacy and safety of chiglitazar and thiazolidinediones (TZDs). In patients with type 2 diabetes, compared with TZDs, chiglitazar induced favorable glycemic and lipidemic control, preserved β-cell function, without increasing safety concerns.